{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:13:22Z","timestamp":1790723602322,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015438","name":"International Society on Thrombosis and Haemostasis Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jtha.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:26:22Z","timestamp":1770164782000},"page":"1886-1895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8278-9428","authenticated-orcid":false,"given":"Lilianne Esm\u00e9e","family":"van Stam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget Jane","family":"Daisy Horstman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-3485","authenticated-orcid":false,"given":"Pantep","family":"Angchaisuksiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-1763","authenticated-orcid":false,"given":"Manuel","family":"Carcao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3494-9823","authenticated-orcid":false,"given":"Gili","family":"Kenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-2439","authenticated-orcid":false,"given":"Christoph","family":"K\u00f6nigs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5781-7669","authenticated-orcid":false,"given":"Johnny","family":"Mahlangu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7113-4028","authenticated-orcid":false,"given":"Maria Elisa","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3083-7093","authenticated-orcid":false,"given":"Suely Meireles","family":"Rezende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9415","authenticated-orcid":false,"suffix":"Jr.","given":"Robert Francis","family":"Sidonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5032-5020","authenticated-orcid":false,"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6013-1254","authenticated-orcid":false,"given":"Guy","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0904-4360","authenticated-orcid":false,"given":"Karin","family":"Fijnvandraat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1957-4122","authenticated-orcid":false,"given":"Samantha Claudia","family":"Gouw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1111\/bcp.14838","article-title":"Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective","volume":"87","author":"Tomeo","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jtha.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O\u2019Hara","year":"2018","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.jtha.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtha.2022.11.020","article-title":"Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort","volume":"21","author":"Fischer","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.01.006_bib6","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.01.006_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102461","article-title":"Inhibitor development according to concentrate after 50 exposure days in severe hemophilia: data from the European HAemophilia Safety Surveillance (EUHASS)","volume":"8","author":"Fischer","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/17474086.2020.1739518","article-title":"Patients with hemophilia A and inhibitors: prevention and evolving treatment paradigms","volume":"13","author":"Lillicrap","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"Suppl 6","key":"10.1016\/j.jtha.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.257.5073.1130","article-title":"Maintenance of in vivo tolerance by persistence of antigen","volume":"257","author":"Ramsdell","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.jtha.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"STROBE initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2026.01.006_bib16","author":"Maldonado"},{"key":"10.1016\/j.jtha.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1080\/13696998.2019.1669614","article-title":"Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events","volume":"22","author":"Patel","year":"2019","journal-title":"J Med Econ"},{"key":"10.1016\/j.jtha.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1111\/jth.15076","article-title":"The factor VIII treatment history of non-severe hemophilia A","volume":"18","author":"Abdi","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/hae.14959","article-title":"Emicizumab use in infancy: a survey of United States pediatric hemophilia treatment center medical directors","volume":"30","author":"Cohen","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/hae.14847","article-title":"Dilemmas on emicizumab in children with haemophilia A: a survey of strategies from PedNet centres","volume":"29","author":"Ranta","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.01.006_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2025.109307","article-title":"A survey on clinical practice in monitoring and management of bleeding in children with haemophilia A on emicizumab prophylaxis in the PedNet centres","volume":"249","author":"Ranta","year":"2025","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/hae.70039","article-title":"Trends in treatment of severe haemophilia and impact on inhibitor assessment by the EUHASS Registry","volume":"31","author":"Fischer","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jtha.2024.12.039","article-title":"Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature","volume":"23","author":"van Stam","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/jech.2003.008466","article-title":"Bias","volume":"58","author":"Delgado-Rodr\u00edguez","year":"2004","journal-title":"J Epidemiol Community Health"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626000607?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626000607?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T19:59:46Z","timestamp":1783972786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626000607"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1538783626000607"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.01.006","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}